Clinical Trial Update: Dose Escalation PfSPZ-CVac [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial of PfSPZ-CVac for malaria has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• PfSPZ-CVac (PfSPZ-CVac)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED | Results posted: 2020-07-24